期刊文献+

HPV E6/E7 mRNA表达量与宫颈癌患者预后的关联研究 被引量:3

Analysis of the relationship between HPV E6/E7 mRNA expression and prognosis of cervical carcinoma
下载PDF
导出
摘要 目的研究HPV E6/E7 mRNA的表达量与宫颈癌患者预后的关系。方法实时荧光定时PCR检测宫颈癌患者癌旁正常组织和癌组织中HPV E6/E7 mRNA的表达情况;分析HPV E6/E7 mRNA的表达量与宫颈癌临床病理特征、患者预后的关系。结果宫颈癌组织中HPV E6/E7 mRNA的表达明显高于癌旁正常组织。高表达HPV E6/E7 mRNA与肿瘤大小(P=0.025)和癌旁浸润(P=0.031)呈正相关。另外,高表达HPV E6/E7 mRNA还与低总生存率(P=0.032)和无瘤生存率(P=0.02)相关。多变量分析发现,HPV E6/E7 mRNA的表达是一个独立的预后因子。结论 HPV E6/E7 mRNA的表达在宫颈癌的发生、发展中起重要作用,是患者预后的重要评价因子。 Objective: To investigate the HPV E6 / E7 mRNA expression in cervical carcinoma and to estimate its clinical significance. Methods: The expression of HPV E6 / E7 mRNA was evaluated by Real- time PCR in cervical cancer and adjacent normal cervical tissues. The correlation between HPV E6 / E7 mRNA expression and clinicopathological features were statistically analyzed. Results: HPV E6 / E7 mRNA expression was significantly higher in cervical cancer tissues compared with that in adjacent normal cervix. High HPV E6 / E7 mRNA expression was positively correlated with tumor size( P= 0. 025) and parametrial infiltration( P = 0. 031). Moreover,high levels of HPV E6 / E7 mRNA was associated with lower overall survival( P = 0. 032) and recurrent- free survival( P = 0. 02). Multivariate analysis showed that the expression of HPV E6 / E7 mRNA was an independent factor of recurrent- free survival for the patients with cervical carcinoma Conclusion: HPV E6 / E7 mRNA expression may play an important role in the development and progression of cervical carcinoma,and may be a potential factor for cervical carcinoma prognosis.
机构地区 廉江市人民医院
出处 《泰山医学院学报》 CAS 2015年第12期1369-1372,共4页 Journal of Taishan Medical College
关键词 宫颈癌 HPV E6/E7 mRNA的表达 预后 cervical carcinoma HPV E6 / E7 mRNA prognosis
  • 相关文献

参考文献15

  • 1Colombo N,Carinelli S,Colombo A,Marini C,Rollo D and Sessa C.Cervical cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2012,23(7):vii27-32.
  • 2Arbyn M,Castellsague X,de Sanjose S,et al.Worldwide burden of cervical cancer in 2008[J].Ann Oncol,2011,22(12):2675-2686.
  • 3Tao X,Hu W,Ramirez PT and Kavanagh JJ.Chemotherapy for recurrent and metastatic cervical cancer[J].Gynecol Oncol,2008,110(3 Suppl 2):S67-71.
  • 4Kruse AJ,Skaland I,Janssen EA,et al.Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions:role of markers of proliferative activity and differentiation and Rb availability[J].Int J Gynecol Pathol,2004,23(2):100-9.
  • 5贾政军,周玉春,胡蓉,彭向京,黄定梅,王华,王丹,何思.HPV E6/E7mRNA和HC2-HPV-DNA检测对宫颈病变筛查的意义[J].湖南师范大学学报(医学版),2012,9(4):51-54. 被引量:11
  • 6Pietrzak B,Mazanowska N,Ekiel A.M.,et al.Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients:an observational study[J].Virol J,2012,9(9):117-122.
  • 7周星,赵文明,陈雪,周炳娟,乔海芝,陈红,张金库.HPV E6/E7 mRNA检测在宫颈癌筛查中的应用[J].中国热带医学,2014,14(12):1493-1495. 被引量:4
  • 8Katase K,Teshima H,Hirai Y,et al.Natural history of cervica human papillomavirus lesios[J].Intervirology,1995,38(3-4):192-194.
  • 9Czegledy J,Veress G,Konya J,et al.Genital human papillomavirus(HPV)infection in Hungarian women[J].Aacta Microbiologyca Hungarica,1993,40(2):115-122.
  • 10黄宝英,周伦顺,富显果,余兰,卢少玲,陈惠华,缪韵仪,刘桐宇,lulu zhang.HPV E6/E7 mRNA检测对宫颈癌筛查意义的初步评价[J].中华肿瘤防治杂志,2013,20(14):1061-1064. 被引量:34

二级参考文献44

  • 1王华,陈亚宝,叶丽华,叶军,袁冬兰.应用支链DNA技术检测人乳头瘤病毒E6/E7mRNA在宫颈疾病筛查中的价值[J].中华临床医师杂志(电子版),2011,5(15):4362-4366. 被引量:29
  • 2章文华,吴令英,白萍,李淑敏,张蓉,李斌,孙建衡,吴爱如.ⅠB期和ⅡA期宫颈癌患者的预后因素分析[J].中华肿瘤杂志,2004,26(8):490-492. 被引量:41
  • 3冯淑瑜,张彦娜,刘建刚.宫颈癌淋巴结转移的高危因素及预后分析[J].癌症,2005,24(10):1261-1266. 被引量:71
  • 4Bolger BS, Dabbas M, Lopes A, et al. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma [J]. Gynecol Oncol,1997,65(2): 309-313.
  • 5Takeshima N, Hirai Y, Katase K, et al. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer [ J ]. Gynecol Oncol, 1998,68 (3): 263-266.
  • 6Monk B J, Cha DS, Walker JL, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage Ⅰ B and Ⅱ A cervical carcinoma [J]. Gynecol Oncol,1994,54( 1 ): 4-9.
  • 7Scambia G, Ferrandina G, Distefano M, et al. Is there a place for a less extensive radical surgery in locally advanced cervical cancer patients? [J]. Gynecol Oncol, 2001,83(2):319-324.
  • 8Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages Ⅰ B, Ⅱ A, and Ⅱ B cervical carcinoma treated with radical hysterectomy [J]. Cancer, 1999,85(7): 1547-1554.
  • 9Benedetti-Panici P, Maneschi F, D'Andrea G, et al. Early cervical carcinoma: the natural history of lymph node involvement redefined on the basis of thorough parametrectomy and giant section study [J]. Cancer, 2000,88 (10):2267-2274.
  • 10Parazzini F, Valsecchi G, Bolis G, et al. Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival[ J]. Gynecol Oncol, 1999,74 ( 1 ): 7- 11.

共引文献123

同被引文献33

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部